Inventiva S.A. (IVA) Q2 2022 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Inventiva Sa.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.009 -- 00:00:04.330 Thank you and welcome everybody to this half-year 00:00:04.330 -- 00:00:05.831 webcast. 00:00:05.831 -- 00:00:10.793 As usual, some disclaimer, we'll be making forward-looking statements, so please have 00:00:10.793 -- 00:00:17.735 a look at our regulatory filings that are available on our website. 00:00:17.735 -- 00:00:22.817 In terms of speakers, I would say we have the classical 00:00:22.817 -- 00:00:27.626 Infinitiva team, myself and Pierre, the co-founders of the company. 00:00:27.626 -- 00:00:31.708 We have Michael, our CMO, and Jean, our CFO. 00:00:31.708 -- 00:00:37.492 But today is a special day for Inventiva, given the very recent 00:00:37.492 -- 00:00:40.853 partnership we signed with CenoBioPharm online in February. 00:00:40.853 -- 00:00:46.016 We are very pleased to have with us Philip Duong, head of the investment, 00:00:46.016 -- 00:00:48.338 who will give us an overview 00:00:48.338 -- 00:00:52.259 of CenoBioPharm activities. 00:00:52.396 -- 00:00:55.078 In terms of agenda, 00:00:55.078 -- 00:00:58.881 I'll give an highlight of the activity 00:00:58.881 -- 00:01:04.166 over the past six months, and then I will share the floor with Philippe, 00:01:04.166 -- 00:01:08.849 with Pierre, with Michael, to provide a pipeline update. 00:01:08.849 -- 00:01:14.234 We will move to the financial section with Jean, near-term catalyst, 00:01:14.234 -- 00:01:18.576 and then we will open the floor for Q&A. 00:01:19.870 -- 00:01:25.174 So, moving now to the highlight section, we start first 00:01:25.174 -- 00:01:30.218 with Lani, our phase three drug in non-alcoholic 00:01:30.218 -- 00:01:32.558 steroid hepatitis. 00:01:36.562 -- 00:01:42.284 A lot of key important milestones have been reached in the past six months. 00:01:42.284 -- ...